NOVN.CH

120.04

+0.45%↑

NOVN.CH

120.04

+0.45%↑

NOVN.CH

120.04

+0.45%↑

NOVN.CH

120.04

+0.45%↑

NOVN.CH

120.04

+0.45%↑

Search

Roche Holding AG

Open

SectorHealthcare

338 -0.35

Overview

Share price change

24h

Current

Min

337.8

Max

341.4

Key metrics

By Trading Economics

Income

1.8B

5.5B

Sales

15B

31B

P/E

Sector Avg

21.01

49.701

Dividend yield

2.98

Profit margin

17.892

Employees

103,249

EBITDA

5.1B

12B

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.98%

2.39%

Market Stats

By TradingEconomics

Market Cap

-21B

268B

Previous open

338.35

Previous close

338

News Sentiment

By Acuity

27%

73%

65 / 345 Healthcare

Roche Holding AG Chart

Past performance is not a reliable indicator of future results.

Related News

7 May 2026, 06:06 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools

23 Apr 2026, 07:46 UTC

Earnings

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23 Apr 2026, 05:40 UTC

Earnings

Roche Backs Full-Year View as Quarterly Sales Rise

9 Mar 2026, 16:43 UTC

Major Market Movers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 Mar 2026, 15:44 UTC

Major Market Movers

Correction to Roche Shares Article

9 Mar 2026, 09:51 UTC

Major Market Movers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 Mar 2026, 09:24 UTC

Major Market Movers

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

13 May 2026, 10:20 UTC

Market Talk
Earnings

Roche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk

7 May 2026, 05:53 UTC

Acquisitions, Mergers, Takeovers

Correct: Roche to Buy PathAI for up to $1.05B

7 May 2026, 05:07 UTC

Acquisitions, Mergers, Takeovers

Roche: Acquisition Expected to Complete in 2H

7 May 2026, 05:06 UTC

Acquisitions, Mergers, Takeovers

Roche: Closing of Deal Subject to Customary Closing Conditions

7 May 2026, 05:06 UTC

Acquisitions, Mergers, Takeovers

Roche to Pay $750M Upfront, Milestone Payments of Up to $300M

7 May 2026, 05:06 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy PathAI for up to $1.5B

7 May 2026, 05:05 UTC

Acquisitions, Mergers, Takeovers

Roche to Buy PathAI

6 May 2026, 22:50 UTC

Earnings

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

27 Apr 2026, 09:54 UTC

Market Talk

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

23 Apr 2026, 08:10 UTC

Market Talk
Earnings

Roche Reports In Line Sales Figures -- Market Talk

23 Apr 2026, 05:04 UTC

Earnings

Roche Backs 2026 View

23 Apr 2026, 05:04 UTC

Earnings

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23 Apr 2026, 05:03 UTC

Earnings

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23 Apr 2026, 05:02 UTC

Earnings

Roche 1Q Group Sales Up 6% at Constant Currency

23 Apr 2026, 05:02 UTC

Earnings

Analysts Saw Roche 1Q Sales at CHF14.73B

23 Apr 2026, 05:01 UTC

Earnings

Roche 1Q Sales CHF14.72B

10 Apr 2026, 11:28 UTC

Market Talk

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 Apr 2026, 11:17 UTC

Market Talk

Roche to Face Significant Currency Headwinds -- Market Talk

11 Mar 2026, 10:57 UTC

Market Talk

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 Mar 2026, 09:43 UTC

Hot Stocks

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 Mar 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 Mar 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 Mar 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

Peer Comparison

Price change

Roche Holding AG Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Sentiment

By Acuity

65 / 345 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat